Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-2280
- Development stage
- Phase 2
- Lead developer
- Antiva Biosciences
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical, Vaginal
01
Overview
ABI-2280 is a small molecule, topical prodrug of an acyclic nucleoside phosphonate developed by Antiva Biosciences. It is designed as a vaginal insert for the treatment of high-grade cervical intraepithelial neoplasia (CIN 2,3) and persistent high-risk human papillomavirus (HPV) infection. The drug acts through a dual mechanism—directly inhibiting human intracellular DNA polymerases required for HPV replication and inducing apoptosis in HPV-infected cells while sparing normal cells. This targeted approach provides both anti-proliferative and antiviral effects across all genotypes of HPV[1][2][3][5][8].
- Other names
- acyclic nucleoside phosphonate prodrug
02
Targets
POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on ABI-2280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-2280.